| scholarly article | Q13442814 |
| P50 | author | Robert Califf | Q19281782 |
| Christopher M O'Connor | Q64689171 | ||
| Mona Fiuzat | Q90936334 | ||
| P2093 | author name string | Anju Nohria | |
| Lynne W Stevenson | |||
| Monica R Shah | |||
| Donna M Mancini | |||
| Margaret Bowers | |||
| Manju Bhapkar | |||
| P433 | issue | 8 | |
| P921 | main subject | heart failure | Q181754 |
| patient | Q181600 | ||
| P304 | page(s) | 613-621 | |
| P577 | publication date | 2011-05-28 | |
| P1433 | published in | Journal of Cardiac Failure | Q2134415 |
| P1476 | title | The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure | |
| P478 | volume | 17 |
| Q37171880 | A review on B-type natriuretic peptide monitoring: assays and biosensors |
| Q48120145 | Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study). |
| Q59767864 | B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data |
| Q38235223 | B-type natriuretic peptide-guided therapy: a systematic review |
| Q30238936 | B-type natriuretic peptide-guided treatment for heart failure. |
| Q88711582 | Biomarker Guided Therapy in Chronic Heart Failure |
| Q38967512 | Can Natriuretic Peptides be Used to Guide Therapy? |
| Q92761146 | Cardiac biomarkers in dialysis |
| Q39493213 | Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissi |
| Q37041145 | Contemporary strategies in the diagnosis and management of heart failure |
| Q37995246 | Developments in heart failure 2011. |
| Q48316825 | Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure |
| Q35179984 | Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials |
| Q27012693 | Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis |
| Q57705901 | Essential components in natriuretic peptide-guided management of heart failure: an intervention synthesis |
| Q64233573 | Natriuretic Peptides in Chronic Heart Failure |
| Q92377424 | Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications |
| Q89868292 | Natriuretic peptide-directed medical therapy: a systematic review |
| Q38161695 | Natriuretic peptide-guided heart failure management |
| Q34614873 | Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials |
| Q38099221 | Natriuretic peptide-guided therapy: further research required for still-unresolved issues |
| Q27012872 | Natriuretic peptides as biomarkers in heart failure |
| Q38120091 | Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. |
| Q55409538 | Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine. |
| Q89474512 | Optimal Endpoints of Acute Heart Failure Therapy |
| Q38184967 | Polypharmacy in heart failure patients. |
| Q34324771 | Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure |
| Q27002436 | Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies |
| Q41604218 | Responder to BNP-guided treatment in heart failure. The process of defining a responder |
| Q87844785 | The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study |
| Q30434020 | The potential value of integrated natriuretic peptide and echo-guided heart failure management |
| Q43513997 | The role of B-type natriuretic Peptide testing in guiding outpatient heart failure treatment |
| Q38063118 | The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure |
| Q90745886 | The role of natriuretic peptides in the management, outcomes and prognosis of sepsis and septic shock |
| Q38613842 | Using biomarkers to guide heart failure management |
| Q37696493 | Variability of biomarkers in patients with chronic heart failure and healthy controls |
| Q52581574 | What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. |
| Q35792547 | Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials |
Search more.